drugset / Trial / NCT02113657
T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
Phase 0
Completed
30 enrolled
M.D. Anderson Cancer Center
Bristol-Myers Squibb · collabHigh Impact Clinical Research Support Program · collabStand Up To Cancer · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to study the impact of ipilimumab on the immune system of patients currently receiving hormone therapy. The safety of these drug combinations will also be studied. This is an investigational study. Ipilimumab is FDA approved and commercially available for the treatment of melanoma. Its use to treat prostate cancer is investigational. Up to 30 patients will take part in this study. All will be enrolled at MD Anderson.
Timeline
- Start
- 2014-08-20
- Primary completion
- 2019-11-04
- Completion
- 2019-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | Intravenous |